<DOC>
	<DOCNO>NCT01257230</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety 48-week treatment two dos tiotropium bromide compare placebo adolescent patient moderate persistent asthma . Efficacy safety assess measure lung function parameter evaluate effect asthma exacerbation , Quality life , health care resource utilisation number adverse event .</brief_summary>
	<brief_title>Efficacy Safety 2 Doses Tiotropium Via Respimat Compared Placebo Adolescents With Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient parent ( legally accept caregiver ) must sign date inform consent consistent ICHGCP guideline local legislation prior participation trial . 2 . Male female patient 12 17 year age . 3 . All patient must least 3 month history asthma time enrolment trial . The diagnosis asthma confirm visit 1 bronchodilator reversibility test . 4 . All patient must maintenance treatment inhaled corticosteroid stable medium dose least 4 week Visit 1 . 5 . All patient must symptomatic ( partly control ) Visit 1 ( screen ) randomisation define Asthma Control Questionnaire ( ACQ ) mean score equal 1.5 . 6 . All patient must prebronchodilator FEV1 equal 60 % less equal 90 % predict normal Visit 1 . Variation absolute FEV1 value Visit 1 compare Visit 2 must within ± 30 % . 7 . All patient must increase FEV1 equal 12 % 200 mL 400 µg salbutamol ( albuterol ) Visit 1 . If patient low age range ( e.g. , 12 14 year old ) exhibit small total lung volume , positive reversibility test might base solely relative ( 12 % ) postbronchodilator response . 8 . All patient neversmokers exsmokers stop smoke least one year prior enrolment . 9 . Patients able use Respimat® inhaler correctly . 10 . Patients must able perform trial related procedure include technically acceptable spirometric manoeuvre . Exclusion criterion : 1 . Patients significant disease asthma . 2 . Patients clinically relevant abnormal screen haematology blood chemistry 3 . Patients history congenital acquire heart disease , and/or hospitalise cardiac syncope failure past year . 4 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year . 5 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . 6 . Patients lung disease asthma ( e.g . Cystic Fibrosis ) . In case expremature infant , history significant bronchopulmonary dysplasia regard exclusion criterion . 7 . Patients know active tuberculosis . 8 . Patients significant alcohol drug abuse within past two year . 9 . Patients undergone thoracotomy pulmonary resection . 10 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior screen visit ( Visit 1 ) . 11 . Patients know hypersensitivity anticholinergic drug , Benzalkonium chloride ( BAC ) , Ethylenediaminetetraacetic acis ( EDTA ) component tiotropium inhalation solution . 12 . Pregnant nursing adolescent female patient 13 . Sexually active female patient childbearing potential use highly effective method birth control . 14 . Patients take investigational drug within 4 week prior Visit 1 . 15 . Patients treat longacting anticholinergic ( e.g . tiotropium Spiriva ) within four week prior screen ( Visit 1 ) . 16 . Patients unable comply pulmonary medication restriction prior randomisation . 17 . Patients treat AntiIgE treatment ( Omalizumab Xolair ) within last 6 month prior screen . 18 . Patients treated systemic ( oral intravenous ) corticosteroid within 4 week prior screen ( Visit 1 ) . 19 . Patients treat longacting theophylline preparation within 2 week prior screen ( Visit 1 ) runin period 20 . Patients treat nonapproved accord international guideline recommend ¿experimental¿ drug routine asthma therapy . 21 . Patients acute asthma exacerbation respiratory tract infection 4 week prior Visit 1 . 22 . Patients require 10 puff rescue medication ( salbutamol/albuterol ) per day 2 consecutive day runin period . 23 . Patients previously randomise trial currently participate another study . 24 . Patients treat oral betablocker medication . 25 . Patients know narrowangle glaucoma , disease anticholinergic treatment contraindicate . 26 . Patients renal impairment , define creatinine clearance le 50 mL/min/1.73 m2 Body Surface Area calculate Schwartz formula .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>